Microvascular Outcomes in the ACCORD Trial

Intensive glycemic control did not lower the incidence of microvascular adverse outcomes.

In the ACCORD trial, 10,000 patients with type 2 diabetes (mean age, 62; average duration of diabetes, 10 years) were randomized to receive intensive or standard glycemic control; choice of antidiabetic agents was individualized. The main purpose of ACCORD was to determine whether intensive treatment (target glycosylated hemoglobin [HbA_1c] level, ≤6%) improved cardiovascular outcomes. The trial was halted after an average follow-up of 3.5 years, when overall and cardiovascular mortality were significantly higher with intensive than with standard treatment (JW Gen Med Jun 6 2008). Now, the researchers present microvascular outcomes.

The principal composite microvascular outcome was end-stage renal disease, rise of serum creatinine to >3.3 mg/…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Microvascular Outcomes in the ACCORD Trial

Topics

Reviewing Author